Literature DB >> 20672899

Hemangiopericytoma: long-term outcome revisited. Clinical article.

Marco Schiariti1, Pablo Goetz, Hussien El-Maghraby, Jignesh Tailor, Neil Kitchen.   

Abstract

OBJECT: Hemangiopericytomas are rare tumors that behave aggressively with a high rate of local recurrence and distant metastases. With the aim of determining the outcome and response to various treatment modalities, a series of 39 patients who underwent microsurgical resection for primary meningeal hemangiopericytoma over a 24-year period is presented.
METHODS: Patients with hemangiopericytoma were identified from histopathology records and their medical records were analyzed retrospectively by 2 independent reviewers to collect data on surgical treatment, adjuvant therapy, postoperative course, local or distant recurrence, and follow-up.
RESULTS: Of the 39 patients, 19 were male and 20 were female. Mean patient age was 44.1 years. Thirty-four tumors were intracranial and 5 were spinal. The mean follow-up period was 123 months. Twenty-eight patients developed local recurrence. The recurrence rate at 1, 5, and 15 years was 3.5%, 46%, and 92%, respectively. Extraneural metastasis occurred in 8 patients (26%) at an average of 123 months after initial surgery. Recurrences and metastases were treated by surgical excision, external beam radiation therapy (EBRT), chemotherapy, and/or stereotactic radiosurgery. Adjuvant EBRT following initial surgery was found to extend the disease-free interval from 154 months to 254 months, although it did not prevent the development of metastasis. In those patients with EBRT and complete resection, the mean recurrence-free interval was found to be 126.3 months longer (p = 0.04) and overall survival 126 months longer than without EBRT. Furthermore, adjusting for resection, patients undergoing EBRT had 0.33 times increased risk of recurrence compared with those who did not (p = 0.03). A majority of patients remained able to live independently despite revision surgery for recurrence.
CONCLUSIONS: The mean follow-up of this patient series represents the longest follow-up duration published to date and demonstrates extended survival in a significant number of patients with hemangiopericytoma. Gross-total resection followed by adjuvant EBRT provides patients with the highest probability of an increased recurrence-free interval and overall survival. Prolonged survival justifies long-term follow-up and aggressive treatment of initial, recurrent, and metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20672899     DOI: 10.3171/2010.6.JNS091660

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  57 in total

1.  Haemangiopericytoma with no dural attachment.

Authors:  Emily Spence; Ramesh Chelvarajah; Colin Shieff
Journal:  BMJ Case Rep       Date:  2012-01-18

2.  A review of solitary fibrous tumor/hemangiopericytoma tumor and a comparison of risk factors for recurrence, metastases, and death among patients with spinal and intracranial tumors.

Authors:  Enrico Giordan; Elisabetta Marton; Alexandra M Wennberg; Angela Guerriero; Giuseppe Canova
Journal:  Neurosurg Rev       Date:  2020-06-18       Impact factor: 3.042

Review 3.  Spinal hemangiopericytoma: an institutional experience and review of literature.

Authors:  Amitabha Das; Pankaj Kumar Singh; Vaishali Suri; Mukund N Sable; Bhawani Shankar Sharma
Journal:  Eur Spine J       Date:  2015-02-08       Impact factor: 3.134

4.  Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs.

Authors:  Guangquan Wei; Xiaowei Kang; Xianping Liu; Xing Tang; Qinlong Li; Juntao Han; Hong Yin
Journal:  Mol Clin Oncol       Date:  2015-04-02

5.  Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system.

Authors:  Connor J Kinslow; Raj S Rajpara; Cheng-Chia Wu; Samuel S Bruce; Peter D Canoll; Shih-Hsiu Wang; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Tony J C Wang
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

6.  Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.

Authors:  Connor J Kinslow; Samuel S Bruce; Ali I Rae; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Adam M Sonabend; Tony J C Wang
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

7.  Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.

Authors:  Seung Hyuck Jeon; Sung-Hye Park; Jin Wook Kim; Chul-Kee Park; Sun Ha Paek; Il Han Kim
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

8.  Intracranial Hemangiopericytomas: Recurrence, Metastasis, and Radiotherapy.

Authors:  Ankur R Patel; Bruno C Flores; Vin Shen Ban; Kimmo J Hatanpaa; Bruce E Mickey; Samuel L Barnett
Journal:  J Neurol Surg B Skull Base       Date:  2017-03-01

9.  Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease.

Authors:  Tarini Ratneswaren; Florence Rosie Avila Hogg; Mathew Joseph Gallagher; Keyoumars Ashkan
Journal:  J Neurooncol       Date:  2018-03-17       Impact factor: 4.130

10.  Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system.

Authors:  Deborah Boyett; Connor J Kinslow; Samuel S Bruce; Adam M Sonabend; Ali I Rae; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Simon K Cheng; Tony J C Wang
Journal:  J Neurooncol       Date:  2019-05-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.